Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.

Saved in:
Bibliographic Details
Title: Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Authors: Liao DS; Retina-Vitreous Associates Medical Group, Beverly Hills, California. Electronic address: dave_liao@laretina.com., Grossi FV; Apellis Pharmaceuticals, Inc, Waltham, Massachusetts., El Mehdi D; Apellis Pharmaceuticals, Inc, Waltham, Massachusetts., Gerber MR; Apellis Pharmaceuticals, Inc, Waltham, Massachusetts., Brown DM; Vitreoretinal Consultants, Methodist Hospital, Houston, Texas., Heier JS; Ophthalmic Consultants of Boston, Boston, Massachusetts., Wykoff CC; Retina Consultants of Houston, Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas., Singerman LJ; Retina Associates of Cleveland, Cleveland, Ohio., Abraham P; Black Hills Regional Eye Institute, Rapid City, Iowa., Grassmann F; Institute of Human Genetics, University of Regensburg, Regensburg, Germany; Karolinska Institutet, Stockholm, Sweden., Nuernberg P; University of Cologne, Cologne, Germany., Weber BHF; Institute of Human Genetics, University of Regensburg, Regensburg, Germany., Deschatelets P; Apellis Pharmaceuticals, Inc, Waltham, Massachusetts., Kim RY; Apellis Pharmaceuticals, Inc, Waltham, Massachusetts., Chung CY; Apellis Pharmaceuticals, Inc, Waltham, Massachusetts., Ribeiro RM; Apellis Pharmaceuticals, Inc, Waltham, Massachusetts., Hamdani M; Apellis Pharmaceuticals, Inc, Waltham, Massachusetts., Rosenfeld PJ; Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida., Boyer DS; Retina-Vitreous Associates Medical Group, Los Angeles, California., Slakter JS; Vitreous Retina Macula Consultants of New York, New York; New York University School of Medicine, New York, New York., Francois CG; Apellis Pharmaceuticals, Inc, Waltham, Massachusetts.
Source: Ophthalmology [Ophthalmology] 2020 Feb; Vol. 127 (2), pp. 186-195. Date of Electronic Publication: 2019 Jul 16.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1549-4713
DOI:10.1016/j.ophtha.2019.07.011